← Back to Clinical Trials
Recruiting NCT07628244

NCT07628244 Comparison of Two General Anesthesia Maintenance Strategies on Intraoperative Visibility During Arthroscopic Rotator Cuff Surgery: A Randomized Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07628244
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Nice
Condition Rotator Cuff Injuries
Study Type INTERVENTIONAL
Enrollment 110 participants
Start Date 2026-06-18
Primary Completion 2026-06-18

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Inhalation anesthesiaContinuous intravenous anesthesia

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 110 participants in total. It began in 2026-06-18 with a primary completion date of 2026-06-18.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Shoulder arthroscopy is one of the most common orthopedic procedures, and the quality of the surgeon's view inside the joint is critical to its safety and success. Unlike limb surgery, no tourniquet can be applied to the shoulder, so surgical visibility depends almost entirely on how much bleeding occurs within the joint - which is itself influenced by the anesthetic drugs used to keep the patient asleep. Two standard techniques exist for maintaining general anesthesia: inhaled anesthesia (sevoflurane) and total intravenous anesthesia (TIVA, using propofol). Evidence from other types of keyhole surgery (nasal, ear) suggests that propofol may produce better surgical visibility, possibly because sevoflurane causes slightly greater dilation of the smallest blood vessels in tissue, leading to more bleeding into the joint. However, in shoulder arthroscopy specifically, the data are scarce and contradictory. CLEAR-SHOULDER is a randomized, single-blind trial designed to determine whether propofol-based intravenous anesthesia provides superior intraoperative visibility compared to sevoflurane-based inhaled anesthesia during arthroscopic rotator cuff repair. Surgical visibility will be assessed from blinded video recordings of each procedure using the validated modified Fromme-Boezaart score. An exploratory artificial intelligence analysis of the arthroscopic videos will also be conducted. Secondary outcomes include operating time, irrigation fluid consumption, hemodynamic stability, vasopressor requirements, surgeon satisfaction, postoperative recovery, and environmental impact of each anesthetic strategy.

Eligibility Criteria

Inclusion Criteria: 1. Patient aged 18 or over 2. Patient scheduled for elective rotator cuff repair arthroscopy (RCRA), performed in the "beach-chair" position under general anesthesia combined with an interscalene block (with or without standard associated procedures such as acromioplasty and/or tenotomy/tenodesis of the long biceps). Procedures for instability (Bankart/Latarjet), fractures, capsulitis, simple lavage, or any arthroscopy not focused on rotator cuff repair (RCR) are not eligible. 3. Patient with an ASA score of I to IV 4. Patient affiliated to a social security scheme, 5. Patient having given written consent following written and oral information. Exclusion Criteria: 1. Patients with a contraindication to any of the study agents, including known hypersensitivity or allergy to any of these agents or to any of their excipients. 2. Patients with known coagulopathy (abnormal PT/INR; platelets \< 100,000/L) or 3. Patients with active preoperative hemarthrosis or local infection. 4. Non-elective (emergency) surgery or a procedure whose initial objective is not rotator cuff repair arthroscopy (RCRA). Note: Intraoperative conversion to open surgery is not an exclusion criterion; it will be considered an intraoperative event and managed in the analysis according to the intention-to-treat (ITT) principle, with a sensitivity analysis procedure described in the statistical plan. 5. Uncooperative patient, inability to consent 6. Pregnant women 7. Patient protected by law under guardianship or curatorship, or unable to participate in a clinical study under article L. 1121-16 of the French Public Health Code.

Contact & Investigator

Central Contact

Jérôme MASCARELLI, Principal investigator

✉ mascarelli.j@chu-nice.fr

📞 +33 4 92 03 29 52

Frequently Asked Questions

Who can join the NCT07628244 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Rotator Cuff Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07628244 currently recruiting?

Yes, NCT07628244 is actively recruiting participants. Contact the research team at mascarelli.j@chu-nice.fr for enrollment information.

Where is the NCT07628244 trial being conducted?

This trial is being conducted at Nice, France.

Who is sponsoring the NCT07628244 clinical trial?

NCT07628244 is sponsored by Centre Hospitalier Universitaire de Nice. The trial plans to enroll 110 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology